How has AbCellera Biologics Inc.'s NOW scheme contingency payable changed year-over-year?

AbCellera Biologics Inc.'s NOW scheme contingency payable increased by 12.6% year-over-year, from $164.41M to $185.05M.

What is the long-term trend for AbCellera Biologics Inc.'s NOW scheme contingency payable?

Over 2 years (2023 to 2025), AbCellera Biologics Inc.'s NOW scheme contingency payable has grown at a 33.4% compound annual growth rate (CAGR), from $103.03M to $183.44M.

AbCellera Biologics Inc. ABCL NOW Scheme contingency payable

NOW Scheme contingency payable at other companies

Energy FuelsUUUU

$1.77M+2.6%

InsmedINSM

$270.31M+69.0%

NWN

Northwest NaturalNWN

$0—

Texas Pacific LandTPL

$0—

Covenant Logistics GroupCVLG

-$208.75K-4.4%

ConocoPhillipsCOP

$0-100%

Segments

By geography

See full

Canada$81.15M-3.6%

CA-BC$24.79M-6.2%

Other financials

Income statement

See full

Revenue$8.3M+96.3%

Operating income-$57.5M+8.2%

Net income-$43.2M+5.4%

EPS (diluted)-$0.14+6.7%

Balance sheet

See full

Cash & equivalents$102.1M-44.6%

Total debt$140.2M+107%

Total equity$938.1M-8.3%

Total assets$1.3B-2.8%

Cash flow

See full

Operating cash flow-$33.5M-190%

CapEx$3.8M-64.0%

Free cash flow-$37.4M-68.3%

Valuation

See full

Market cap$1.84B+59.2%

Enterprise value$1.88B+100.0%

P/S23.3×-26.8×

Profitability

See full

Operating margin-267.6%-120pp

Net margin-181.7%-77.9pp

FCF margin-238.9%-90.9pp

Returns & leverage

See full

Return on equity-14.7%-0.8pp

Debt / equity0.1×+0.1×

Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:GovernmentAssistanceLiability.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s now scheme contingency payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AbCellera Biologics Inc.'s NOW scheme contingency payable?: AbCellera Biologics Inc. (ABCL) reported NOW scheme contingency payable of $185.05M in Q1 2026.
How has AbCellera Biologics Inc.'s NOW scheme contingency payable changed year-over-year?: AbCellera Biologics Inc.'s NOW scheme contingency payable increased by 12.6% year-over-year, from $164.41M to $185.05M.
What is the long-term trend for AbCellera Biologics Inc.'s NOW scheme contingency payable?: Over 2 years (2023 to 2025), AbCellera Biologics Inc.'s NOW scheme contingency payable has grown at a 33.4% compound annual growth rate (CAGR), from $103.03M to $183.44M.